Urits, Berger, Hasoon, Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA. Gress, Charipova, Georgetown University School of Medicine, Washington, DC. Li, Medical College of Wisconsin, Wauwatosa, WI. Cornett, Louisiana State University Health Sciences Center, Department of Anesthesiology, New Orleans, LA. Kassem, Mount Sinai Medical Center, Department of Anesthesiology, Miami Beach, FL. Kaye, Louisiana State University Health Shreveport, Department of Anesthesiology, Shreveport, LA. Viswanath, Valley Anesthesiology and Pain Consultants - Envision Physician Services, Phoenix, AZ. University of Arizona College of Medicine-Phoenix, Phoenix, AZ. Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE.
Psychopharmacol Bull. 2020 May 19;50(2):56-67.
This is a comprehensive review of the association between cannabis use and psychological disorders. It reviews the latest and seminal evidence that is available and attempts to conclude the strength of such association.
Cannabis is a flowering plant with psychoactive properties, attributed to cannabinoids that naturally occur within the plant. These act through the CB1 and CB2 receptors to inhibit GABA and glutamate release, as well through other forms of neuromodulation through the modulation of the endocannabinoid system (eCBs); a system that is otherwise involved in different pathways, including reward, memory, learning, and pain. Recent societal changes have increased the use of both medical and recreational cannabis. Patients with mental illness are considered more vulnerable and are prone to reward-seeking behavior. Cannabis use disorder (CUD) has been shown to have an increased prevalence in individuals with mental illness, creating an explosive cocktail. Approximately 1 in 4 patients with schizophrenia are also diagnosed with CUD. Cannabis use is associated with 2-4 times the likelihood of developing psychosis in healthy individuals. It has also been associated with multiple poor prognostic factors in schizophrenia, as well as in patients with a history of psychosis who do not meet diagnostic criteria for schizophrenia. Cannabis has been linked with anxiety; THC has been shown to elicit anxiety; however, anxiety is also a trigger for cannabis use. However, a recent large meta-analysis did not find a convincing link between cannabis and anxiety. This was reiterated in a recent epidemiological study that did not find such a correlation; however, it did identify a link between cannabis use, substance disorder, alcohol use disorder, drug use disorder, and nicotine dependence. Similarly, contradicting data exists regarding the link of depression and cannabis use.
Cannabis use is increasing with recent societal shifts; however, its interaction with mental health is less well understood. CUD is highly prevalent in individuals with mental health disorders, especially those with other substance abuse disorders. There is evidence to support that cannabis use may trigger and worsen psychosis and schizophrenia. The link with depression and anxiety is less clear and needs further investigation. Personality disorder is linked with substance use disorder and shares similar risk factors with CUD.
这是一篇关于大麻使用与心理障碍之间关联的综合综述。本文回顾了最新和主要的现有证据,并试图得出这种关联的强度。
大麻是一种具有精神活性的开花植物,其特性归因于植物体内天然存在的大麻素。这些大麻素通过 CB1 和 CB2 受体抑制 GABA 和谷氨酸的释放,通过调节内源性大麻素系统(eCBs)的其他形式的神经调制,以及通过调节其他形式的神经调制来发挥作用;该系统还参与包括奖励、记忆、学习和疼痛在内的不同途径。最近社会的变化增加了医用和消遣用大麻的使用。患有精神疾病的患者被认为更容易受到影响,并且更容易产生寻求奖励的行为。大麻使用障碍(CUD)在患有精神疾病的个体中更为普遍,这形成了一个爆炸性的组合。大约 1/4 的精神分裂症患者也被诊断出患有 CUD。在健康个体中,大麻使用与发展为精神病的可能性增加 2-4 倍相关。它也与精神分裂症患者的多个不良预后因素以及不符合精神分裂症诊断标准的精神病病史患者相关。大麻与焦虑有关;THC 已被证明会引起焦虑;然而,焦虑也是大麻使用的一个触发因素。然而,最近的一项大型荟萃分析并没有发现大麻和焦虑之间有令人信服的联系。最近的一项流行病学研究也没有发现这种相关性,该研究再次强调了大麻使用与物质障碍、酒精使用障碍、药物使用障碍和尼古丁依赖之间的联系。同样,关于大麻使用与抑郁之间关联的研究结果也存在矛盾。
随着最近社会的转变,大麻的使用正在增加;然而,它与心理健康的相互作用还不太清楚。CUD 在患有精神健康障碍的个体中非常普遍,尤其是那些同时患有其他物质滥用障碍的个体。有证据支持大麻使用可能引发和加重精神病和精神分裂症。与抑郁和焦虑的关联不太清楚,需要进一步研究。人格障碍与物质使用障碍有关,并且与 CUD 有相似的风险因素。